Molecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements Aug 02, 2017 8:30am EDT
Molecular Templates Announces Presentations Featuring Engineered Toxin Bodies at the 2017 American Association for Cancer Research (AACR) Annual Meeting Mar 30, 2017 4:01pm EDT
Molecular Templates to Present Clinical and Preclinical Data for MT-3724 and Next Generation Engineered Toxin Bodies (ETBs) at the 2016 American Association for Cancer Research (AACR) Annual Meeting Apr 06, 2016 8:30am EDT
Molecular Templates Collaborates with the MD Anderson Cancer Center on Research of MT-3724 in Chemo-Resistant Aggressive B-Cell Lymphomas Oct 08, 2015 8:30am EDT
Molecular Templates Presents Preclinical Data on De-Immunized Engineered Toxin Bodies (ETB) with Novel Immuno-Oncology Capabilities at the 2015 AACR Annual Meeting Apr 16, 2015 8:00am EDT
Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma Mar 05, 2015 8:00am EST
Molecular Templates Presents Preclinical Data on CD38-Targeted Engineered Toxin Body (ETB) at the American Association for Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries to Novel Therapies Sep 24, 2014 8:30am EDT
Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizing Immunotoxin MT-3724 Sep 08, 2014 9:00am EDT
Molecular Templates Presents Preclinical Data on Engineered Toxin Bodies (ETBs) at the AACR Annual Meeting Apr 18, 2014 8:00am EDT
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding Oct 08, 2013 8:00am EDT
